{"title":"InterMune Divests Declining Actimmune® to Focus on Esbriet®","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1746","DOIUrl":null,"url":null,"abstract":"InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i5.1746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
